DIAGNOS Inc. (TSXV:ADK)
Canada
· Delayed Price · Currency is CAD | Market Cap | 20.37M |
| Revenue (ttm) | 103.80K |
| Net Income (ttm) | -4.29M |
| Shares Out | 101.86M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,200 |
| Average Volume | 123,026 |
| Open | 0.2100 |
| Previous Close | 0.2100 |
| Day's Range | 0.2000 - 0.2100 |
| 52-Week Range | 0.1800 - 0.4300 |
| Beta | -0.65 |
| RSI | 39.09 |
| Earnings Date | Jun 6, 2025 |
About DIAGNOS
DIAGNOS Inc. provides software-based services for healthcare sector in Canada, the United States, Mexico, Chile, and internationally. It offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy, as well as allows eye care specialist to visualize normal retinal landmarks and pathological changes. The company also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was fou... [Read more]
Financial Performance
In 2024, DIAGNOS's revenue was 103,797, a decrease of -39.00% compared to the previous year's 170,158. Losses were -4.29 million, 37.4% more than in 2023.
Financial StatementsNews
DIAGNOS Welcomes Founder of National Vision Associates, Ed Weiner, to its Advisory Board for the United States
BROSSARD, Quebec, June 10, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues us...
DIAGNOS Welcomes Former White House Economic Adviser Dr. Tomas J. Philipson to its Advisory Board for the US Market
BROSSARD, Quebec, June 04, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues us...
DIAGNOS Announces the Engagement of Allele Capital Partners
BROSSARD, Quebec, May 23, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues usi...
DIAGNOS Announces Amendment to Convertible Debentures
BROSSARD, Quebec, May 20, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues usi...
DIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application
BROSSARD, Quebec, April 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic healt...
DIAGNOS Provides Additional Information on Amendment to Convertible Debentures
BROSSARD, Quebec, April 14, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic healt...
DIAGNOS Provides Update on its Health Canada Medical Device Licence Application
BROSSARD, Quebec, April 09, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic healt...
DIAGNOS amends terms of convertible debentures
Diagnos (ADK:CA) intends to amend the terms of an aggregate amount of $120,000 of unsecured convertible debentures issued as part of a private placement of unit
DIAGNOS Announces Amendment to Convertible Debentures
BROSSARD, Quebec, March 31, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues u...
DIAGNOS is filing for the Saudi FDA Authorization of Its CARA SYSTEM, an AI Assisted Medical Device
BROSSARD, Quebec, March 12, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues t...
DIAGNOS Announces Amendment to Convertible Debentures
BROSSARD, Quebec, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a leader in early detection of critical health issues usi...
DIAGNOS to File for FDA Pre-Market Authorization of Its AI-Powered CARA SYSTEM and Engages Ora as Regulatory Specialist
BROSSARD, Quebec, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues th...
DIAGNOS to Present at Centurion One Capital 8th Annual Toronto Growth Conference
Brossard, Quebec--(Newsfile Corp. - February 24, 2025) - Diagnos Inc. (TSXV: ADK) (OTCQB: DGNOF) (FSE: 4D4A) ("DIAGNOS" or the "Corporation"), a pioneer in early detection of critical health issues th...
Correction - Diagnos Announces Closing of Private Placement
In the original press release dated February 5, 2025, announcing the closing of a private placement of 6,715,370 units issued at a price of $0.30 per unit, for gross proceeds of $2,014,611, the number...
DIAGNOS Announces Closing of Private Placement
BROSSARD, Quebec, Feb. 05, 2025 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the ...
DIAGNOS Announces Financial Contribution of $400,000 from the Government of Canada
BROSSARD, Quebec, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues th...
DIAGNOS to Present at The Microcap Conference 2025
BROSSARD, Quebec, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues th...
DIAGNOS Announces the Engagement of Promoter
BROSSARD, Quebec, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues th...
DIAGNOS Announces Closing of Private Placement
BROSSARD, Quebec, Oct. 25, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the ...
DIAGNOS Announces the Engagement of Market Maker Consultant
BROSSARD, Quebec, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the ...
DIAGNOS Announces Grant of Stock Options
BROSSARD, Quebec, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the ...
DIAGNOS Announces Voting Results of Meeting of Shareholders
BROSSARD, Quebec, Sept. 26, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the...
DIAGNOS Announces Variation in One Insider Ownership
BROSSARD, Quebec, Sept. 23, 2024 (GLOBE NEWSWIRE) -- In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK), announces that as a res...
DIAGNOS Announces Closing of Private Placement
BROSSARD, Quebec, Sept. 20, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the...
DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders
BROSSARD, Quebec, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the us...